EGFR and non-small cell lung carcinoma: Some newly discovered cytokines, including YES (pp62c-yes) [23], YES/YES-associated protein 1 [24], and NF-1 [25], can increase the sensitivity of NSCLC cells to EGFR-TKIs by activating the AKT or MAPK pathway, showing great research benefits.